Alzheimer's disease (AD), one of the most dreaded neurodegenerative disorders, is characterized by cortical and cerebrovascular amyloid β peptide (Aβ) deposits, neurofibrillary tangles, chronic inflammation, and neuronal loss. Increased bone fracture rates and reduced bone density are commonly observed in patients with AD, suggesting one or more common denominators between both disorders. However, very few studies are available that have addressed this issue. Here, we present evidence for a function of amyloid precursor protein (APP) and Aβ in regulating osteoclast (OC) differentiation in vitro and in vivo. Tg2576 mice, which express the Swedish mutation of APP (APPswe) under the control of a prion promoter, exhibit biphasic effects on OC activation, with an increase of OCs in younger mice (< 4 months old), but a decrease in older Tg2576 mice (> 4 months old). The increase of OCs in young Tg2576 mice appears to be mediated by Aβ oligomers and receptor for advanced glycation end products (RAGE) expression in bone marrow macrophages (BMMs). However, the decrease of OC formation and activity in older Tg2576 mice may be due to the increase of soluble rage (sRAGE) in aged Tg2576 mice, an inhibitor of RANKL-induced osteoclastogenesis. These results suggest an unexpected function of APPswe/Aβ, reveal a mechanism underlying altered bone remodeling in AD patients, and implicate APP/Aβ and RAGE as common denominators for both AD and osteoporosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126661 | PMC |
| http://dx.doi.org/10.1002/jbmr.299 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hearing modulation affects Alzheimer's disease progression linked to brain inflammation: a study in mouse models.
Mol Med
December 2024
Department of Otolaryngology-Head and Neck Surgery, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jaebong-Ro, Dong-Gu, Gwangju, 61469, Republic of Korea.
Background: Recent studies have identified hearing loss (HL) as a primary risk factor for Alzheimer's disease (AD) onset. However, the mechanisms linking HL to AD are not fully understood. This study explored the effects of drug-induced hearing loss (DIHL) on the expression of proteins associated with AD progression in mouse models.
View Article and Find Full Text PDFGut microbiota dysbiosis in Alzheimer's disease (AD): Insights from human clinical studies and the mouse AD models.
Physiol Behav
December 2024
Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA; Deptment of Neuroscience & Regenerative Medicine, Augusta, GA 30912, USA; College of Agriculture, Food, and Natural Resources, Prairie View A&M University, Prairie View, TX 77446, USA; Centre for Healthy Aging, Medical College of Georgia, Augusta University, Augusta, GA, USA; Department of Cell Biology and Anatomy, Medical College of Georgia, Augusta University, GA, USA; Department of Orthopedic Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA. Electronic address:
Alzheimer's Disease (AD) is a debilitating neurocognitive disorder with an unclear underlying mechanism. Recent studies have implicated gut microbiota dysbiosis with the onset and progression of AD. The connection between gut microbiota and AD can significantly affect the prevention and treatment of AD patients.
View Article and Find Full Text PDFFAAH Inhibition Counteracts Neuroinflammation via Autophagy Recovery in AD Models.
Int J Mol Sci
November 2024
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.
Article Synopsis
- Endocannabinoids show promise in reducing neuroinflammation related to Alzheimer's disease (AD) by potentially rebalancing autophagic mechanisms.
- Researchers administered URB597, an FAAH inhibitor that increases anandamide levels, to both microglial cultures and Tg2576 transgenic mice.
- The treatment led to a shift in microglia toward an anti-inflammatory state, reduced amyloid plaque formation, and restored key autophagy markers, indicating a possible therapeutic approach for AD.
Alterations of endocannabinoid signaling and microglia reactivity in the retinas of AD-like mice precede the onset of hippocampal β-amyloid plaques.
J Neurochem
November 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Extra-cerebral manifestations of Alzheimer's disease (AD) develop in the retina, which is, therefore, considered a "window to the brain". Recent studies demonstrated the dysregulation of the endocannabinoid (eCB) system (ECS) in AD brain. Here, we explored the possible alterations of ECS and the onset of gliosis in the retina of AD-like mice.
View Article and Find Full Text PDFmCLAS adaptively rescues disease-specific sleep and wake phenotypes in neurodegeneration.
Sleep Med
December 2024
Department of Neurology, University Hospital Zurich (USZ), Switzerland; Neuroscience Center Zurich (ZNZ), Switzerland; Center of Competence Sleep and Health, University of Zurich (UZH), Switzerland. Electronic address:
Article Synopsis
- Sleep changes are common in Alzheimer's and Parkinson's diseases, affecting brain health during deep sleep.
- A new method called mouse closed-loop auditory stimulation (mCLAS) has been developed to enhance slow-wave activity during deep sleep in models of these diseases.
- Initial findings show that mCLAS can improve sleep patterns in mice, with different effects seen in Alzheimer's versus Parkinson's models, suggesting potential for future sleep-based therapies in neurodegenerative conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!